Sotera Health (SHC)
Provides contract sterilization, gamma technologies, and testing services for healthcare-product safety.
Something off on this page? Send us feedback.
Connects Sterigenics contract sterilization, Nordion gamma technologies and Cobalt-60, and Nelson Labs testing and advisory services. Its three reported businesses form an end-to-end platform for healthcare-product sterilization and safety.
Sterigenics provides contract sterilization for healthcare products. Nordion supplies gamma technologies and Cobalt-60, while Nelson Labs provides testing and advisory services for product safety. Together, their services cover sterilization and safety work across healthcare products.
The three reported businesses form an end-to-end healthcare-product sterilization and safety platform. Sterigenics is the largest revenue contributor, and the platform supports healthcare-product safety worldwide.
These businesses combine legacy specialist capabilities under a public parent rather than operating as informal brands. EO-related claims and the company’s voluntary emission-control investments remain a structural part of the operating context.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | Piper Sandler | Reiterate | Rating: —Target: $24 | Target: $25 |
| Jun 24, 2026 | UBS | Target | Target: — | Target: $19 |
| Jun 5, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $17 | Target: $20 |
| Apr 14, 2026 | Barclays | Reiterate | Rating: —Target: $20 | Target: $18 |
| Jan 9, 2026 | Piper Sandler | Upgrade | Target: $17 | Target: $24 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $356.7M · Total debt $2.27B · Total assets $3.31B · Shareholders' equity $665.6M
- Revenue
- $321.4M
- Operating income
- $106.8M
- Net income
- $53.6M
No dividends on record.
| Institutions | ≈ 103.39% | 295.04M shares | |
|---|---|---|---|
| 318 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 62.54% | 178.46M shares | |
| 19 holders · as of Aug 19, 2026 | |||
| Adds to | 165.93% | ||
285.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 165.93%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act butInsider | 61.57% | 175.70M | filed Feb 11, 2022 |
WP XI Partners, L.P.Institution | 25.59% | 73.04M | filed Nov 12, 2025 |
Sessa Capital Im, L.P.Institution | 9.48% | 27.05M | as of Jun 30, 2026 |
Darsana Capital Partners LPInstitution | 9.46% | 27.00M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.46% | 24.15M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Michael B. Jr. Petras | director, officer: Executive Chairman | −1,144,515 | $18.50 |
| Aug 7, 2026 | Michael P. Rutz | officer: President of Sterigenics | −150,000 | $18.84 |
| May 13, 2026 | GTCR Investment Xi LLC | director, 10 percent owner: | −12,735,301 | $15.17 |
| May 13, 2026 | Warburg Pincus & Co. | director, 10 percent owner: | −19,102,952 | $15.17 |
| Mar 6, 2026 | GTCR Investment Xi LLC | director, 10 percent owner: | −10,000,000 | $15.27 |
